Venetoclax

Red

Brand Name(s):Venclyxto

Indication:Untreated Chronic Lymphocytic Leukaemia

Leukaemia chronic lymphocytic (CLL)

Rationale:1,2

Considered:Jan-17

Review Date:Jan-26

Comments:
NICE TA663
Venetoclax plus obinutuzumab is recommended for untreated CLL in adults, only if there is a 17p deletion or TP53 mutation, or there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab, is unsuitable.